Predictions of metabolic drug-drug interactions using physiologically based modelling: Two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil

Clinical Pharmacokinetics

Volumn 49, Issue 4, 2010, Pages 239-258

  Perdaems, Nathalie ^a   Blasco, Helene ^a   Vinson, Cedric ^a   Chenel, Marylore ^a   Whalley, Sarah ^b   Cazade, Fanny ^a   Bouzom, Francois ^a  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^b Servier Research and Development   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; KETOCONAZOLE; MIDAZOLAM; MIDAZOLAM MALEATE; NORVERAPAMIL; VERAPAMIL;

ACCURACY; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; COMPUTER PROGRAM; CONTROLLED STUDY; DATA BASE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RESEARCH; ENZYME SUBSTRATE; FOOD AND DRUG ADMINISTRATION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MODEL; NORMAL HUMAN; PREDICTION; PRIORITY JOURNAL; SINGLE DRUG DOSE; UNITED STATES;

ALGORITHMS; AREA UNDER CURVE; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; HUMANS; KETOCONAZOLE; METABOLIC CLEARANCE RATE; MIDAZOLAM; MODELS, BIOLOGICAL; MONTE CARLO METHOD; VERAPAMIL;

EID: 77949381133     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11318130-000000000-00000     Document Type: Article

References (68)

1. Krayenbuhl JC, Vozeh S, Kondo-Oestreicher M, et al. Drug-drug interactions of new active substances: mibefradil example. Eur J Clin Pharmacol 1999; 55 (8): 559-565
2. Bjornsson TD, Callaghan JT, Einolf HJ, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 2003; 31 (7): 815-832
3. US FDA Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research. Draft guidance for industry: drug interaction studies-study design, data analysis, and implications for dosing and labeling. Rockville (MD): FDA 2006 Sep [online]. Available from URL: http:// www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm072101.pdf [Accessed 2010 Jan 20]
4. Bachmann KA. Inhibition constants, inhibitor concentrations and the prediction of inhibitory drug-drug interactions: pitfalls, progress and promise. Curr Drug Metab 2006; 7 (1): 1-14
5. Brown HS, Galetin A, Hallifax D, et al. Prediction of in vivo drug-drug interactions from in vitro data: factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4. Clin Pharmacokinet 2006; 45 (10): 1035-1050
6. Lin JH, Pearson PG. Prediction of metabolic drug interactions: quantitative or qualitative. In: Rodrigues D, editor. Drug-drug interaction. New York: Marcel Dekker Inc., 2002: 415-438
7. Youdim KA, Zayed A, Dickins M, et al. Application of CYP3A4 in vitro data to predict clinical drug-drug interactions: predictions ofcompoundsasobjects of interaction. Br J Clin Pharmacol 2008; 65 (5): 680-692
8. Andersson TB, Bredberg E, Ericsson H, et al. An evaluation of the in vitro metabolism data for predicting the clearance and drug-drug interaction potential of CYP2C9 substrates. Drug Metab Dispos 2004; 32 (7): 715-721
9. Rostami-Hodjegan A, Tucker GT. 'In silico' simulations to assess the 'in vivo' consequences on 'in vitro' metabolic drug-drug interactions. Drug Discov Today Technol 2004; 1: 441-448
10. Rostami-Hodjegan A, Tucker GT. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nature Rev Drug Discov 2007; 6: 140-148
11. Yang RSH, Clewell III HJ, Andersen ME. Introduction: a historical perspective of the development and applications of PBPK models. In: Reddy MB, editor. Physiologically based pharmacokinetic modeling. New York: John Wiley & Sons, Inc., 2005: 1-18
12. Nestorov I. Whole body pharmacokinetic models. Clin Pharmacokinet 2003; 42 (10): 883-908
13. Rowland M, BalantL,PeckC. Physiologically based pharmacokinetics indrug development and regulatory science: a workshop report (Georgetown University, Washington, DC, May 29-30, 2002). AAPS PharmSci 2004; 6 (1): E6-12
14. Theil FP, Guentert TW, Haddad S, et al. Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection. Toxicol Lett 2003; 138 (1-2): 29-49
15. Jones HM, Parrot N, Jorga K, et al. A novel strategy for physiologically based predictions of human pharmacokinetics. Clin Pharmacokinet 2006; 45 (5): 511-542
16. Lave T, Parrot N, Grimm HP, et al. Challenges and opportunities with modelling and simulation in drug discovery and drug development. Xenobiotica 2007; 37 (10-11): 1295-1310
17. Krishnan K, Clewell III HJ, Andersen ME. Physiologically based pharmaco-kinetic analyses of simple mixtures. Environ Health Perspect 1994; 102 Suppl. 9: 151-155
18. Tardif R, Charest-Tardif G, Brodeur J, et al. Physiologically based pharma-cokinetic modelling of ternary mixture of alkyl benzenes in rats and humans. Toxicol Appl Pharmacol 1997; 144: 120-134
19. Ozdemir MCK, Tucker GT, Rostami-Hodjegan A. The impact of ketoconazole dosage regimen on midazolam clearance and its prediction using PBPK modelling [abstract]. European Federation for Pharmaceutical Sciences Conference on Optimising Drug Development together with Biosim EU Network of Eexcellence; 2006 Nov 29-Dec 1; Basel
20. Vossen M, Sevestre M, Niederalt C, et al. Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models. Theor Biol Med Model 2007; 4: 13
21. A case study in SPE method development-understanding the dual interaction propertiesof discovery DSC-SCX SPE using verapamil (and metabolite) from serum as a test example. The Reporter Magazine for Europe 2004 Mar 10 [online]. Available from URL: http://www.sigmaaldrich.com/etc/medialib/ docs/Supelco/Bulletin/rep10.Par.0001.File.tmp/rep10.pdf [Accessed 2010 Jan 20]
22. Bu HZ. A literature review of enzyme kinetic parameters for CYP3A4-mediated metabolic reactions of 113 drugs in human liver microsomes: structure-kinetics relationship assessment. Curr Drug Metab 2006; 7 (3): 231-249
23. Bjorkman S, Wada DR, Berling BM, et al. Prediction of the disposition of midazolam in surgical patients by a physiologically based pharmacokinetic model. J Pharm Sci 2001; 90 (9): 1226-1241
24. Shibata Y, Takahashi H, Chiba M, et al. Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: an application of serum incubation method. Drug Metab Dispos 2002; 30 (8): 892-896
25. Robinson MA, Mehvar R. Enantioselective distribution of verapamil and norverapamil into human and rat erythrocytes: the role of plasma protein binding. Biopharm Drug Dispos 1996; 17: 577-587
26. Pauli-Magnus C, von Richter O, Burk O, et al. Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. J Pharmacol Exp Ther 2000; 293 (2): 376-382
27. Huang YC, Colaizzi JL, Bierman RH, et al. Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. Antimicrob Agents Chemother 1986; 30 (2): 206-210
28. Abernethy DR, Wainer IW, Anacleto AI, et al. Verapamil metabolite exposure in older and younger men during steady-state oral verapamil administration. Drug Metab Dispos 2000; 28 (7): 760-765
29. von Moltke L, Greenblatt DJ, Schmider J, et al. Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, nofluoxetine and by azole antifungal agents. J Clin Pharmacol 1996; 36 (9): 783-791
30. Ma B, Prueksaritanont T, Lin JH, et al. Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos 2000; 28 (2): 125-130
31. Yamano K, Yamamoto K, Kotaki H, et al. Quantitative prediction of metabolic inhibition of midazolam by erythromycin, diltiazem and verapamil in rats: implication of concentrative uptake of inhibitors into liver. J Pharmacol Exp Ther 2000; 292 (3): 1118-26 Simcyp® version 7 [computer program]. Sheffield: Simcyp Ltd, 2007
32. Wang YY, Jones R, Hall S. Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab and Dispos 2005; 33 (5): 664-671
33. Tham LS, Lee HS, Wang L, et al. Ketoconazole renders poor CYP3A phenotype status with midazolam as probe drug. Ther Drug Monit 2006; 28: 255-261
34. Chung E, Nafziger AN, Kazierad DJ, et al. Comparison of midazolam and simvastatin as cytochrome P450 3A probes. Clin Pharmacol Ther 2006; 79: 350-361
35. Backman JT, Olkkola KT, Aranko K, et al. Dose of midazolam should be reduced during diltiazem and verapamil treatments. Br J Clin Pharmacol 1994; 37: 221-225
36. Mayhew B, Jones D, Hall S. An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab Dispos 2000; 28 (9): 1031-1037
37. Proctor NJ, Tucker GT, Rostami-Hodjegan A. Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors. Xenobio-tica 2004; 34: 151-178
38. Wilkinson GR, Shand DG. Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther 1975; 18: 377-390
39. Howgate EM, Rowland Yeo K, Proctor NJ, et al. Prediction of in vivo drug clearance from in vitro data. I: Impact of inter-individual variability. Xeno-biotica 2006; 36: 473-497
40. Rowland-Yeo K, Rostami-Hodjegan A, Tucker GT. Abundance of cytochromes P450 in human liver: a meta-analysis. Br J Clin Pharmacol 2004; 57: 687-688
41. Barter ZE, Bayliss MK, Beaune PH, et al. Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr Drug Metab 2007; 8: 33-45
42. Johnson TN, Tucker GT, Tanner MS, et al. Changes in liver volume from birth to adulthood: a meta-analysis. Liver Transpl 2005; 11: 1481-1493
43. Johnson TN, Rostami-Hodjegan A, Tucker GT. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet 2006; 45: 931-956
44. acslXtreme® version 2.3.0.12 [computer program]. Huntsville (AL): Aegis Technologies Group Inc., 2006
45. Wang YH, Jones DR, Hall SD. Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos 2004; 32 (2): 259-266
46. Zhao P, Ragueneau-Majlessi I, Zhang L, et al. Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study. J Clin Pharmacol 2009 Mar; 49 (3): 351-359
47. Chenel M, Bouzom F, Aarons L, et al. Drug-drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 1: comparison of uniresponse and multiresponse designs using PopDes. J Pharmacokinet Pharmacodyn 2008; 35: 635-659
48. Chenel M, Bouzom F, Cazade F, et al. Drug-drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 2: clinical trial results. J Pharmacokinet Pharmacodyn 2008; 35: 661-681
49. Sun D, Yu XL, Hussain MA, et al. In vitro testing of drug absorption for drug 'developability' assessment: forming an interface between in vitro preclinical data and clinical outcome. Curr Opin Drug Discov Devel 2004 Jan; 7 (1): 75-85
50. Mouly S, Paine MF. P-glycoprotein increases from proximal to distal regions of human small intestine. Pharm Res 2003; 20: 1595-1599
51. Berggren S, Gall C, Wollnitz N, et al. Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine. Mol Pharm 2007 Mar-Apr; 4 (2): 252-257
52. van de Kerkhof EG, de Graaf IA, Groothuis GM. In vitro methods to study intestinal drug metabolism. Curr Drug Metab 2007; 8 (7): 658-675
53. GastroPlus™ version 6.1 [computer program]. Lancaster (CA): Simulationsplus, Inc. 2009
54. PK-Sim® version 4.2 [computer program]. Leverkusen: Bayer Technology Services GmbH, 2009
55. Raeissi SD, Hidalgo IJ, Segura-Aguilar J, et al. Interplay between CYP3A-mediated metabolism and polarized efflux of terfenadine and its metabolites in intestinal epithelial Caco-2 (TC7) cell monolayers. Pharm Res 1999; 16 (5): 625-632
56. Tolle-Sander S, Rautio J, Wring S, et al. Midazolam exhibits characteristics of a highly permeable P-glycoprotein substrate. Pharm Res 2003; 20 (5): 757-764
57. Klein HO, Lang R, Weiss E, et al. The influence of verapamil on serum digoxin concentration. Circulation 1982; 65: 998-1003
58. Neuhoff S, Yang J, JameiM, et al. Simulation of the effect of P-glycoprotein on drug absorption in the human gastrointestinal tract [abstract]. 10th European ISSX meeting; 2008 May 18-21; Vienna
59. Gibaldi M, Perrier D. Physiological pharmacokinetic models. In: Swarbrick J, editor. Pharmacokinetics. 2nd ed. New York: Marcel Dekker, Inc., 1982: 355-384
60. PoulinP,Theil FP.A prioripredictionoftissue: plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. J Pharm Sci 2000; 89 (1): 16-35
61. Poulin P, Schoenlein K, Theil FP. Prediction of adipose: plasma partition coefficients for structurally unrelated drugs. J Pharm Sci 2001; 90 (4): 436-447
62. Brown RP, Delp MD, Lindstedt SL, et al. Physiological parameters values for physiologically based pharmacokinetic models. Toxicol Ind Health 1997; 13: 407-487
63. Rodgers T, Leahy D, Rowland M. Physiologically based pharmacokinetic modelling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci 2005; 94 (6): 1259-1276
64. Rodgers T, Leahy D, Rowland M. Tissue distribution of basic drugs: accounting for enantiomeric, compound and regional differences amongst beta-blocking drugs in rat. J Pharm Sci 2005; 94 (6): 1237-1248
65. Ploeger B, Mensinga T, Sips A, et al. A human physiologically-based model for glycyrrhzic acid, a compound subject to presystemic metabolism and enterohepatic cycling. Pharm Res 2000; 17 (12): 1516-1525
66. Yu XL, Crison JR, Amidon GL. Compartmental transit and dispersion model analysis of small intestinal transit flow in humans. Int J Pharm 1996; 140 (1): 111-118
67. Sun D, Lennernas H, Welage LS, et al. Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs. Pharm Res 2002; 19 (10): 1400-1416
68. Paine MF, Khalighi M, Fischer JM, et al. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 1997; 283: 1552-1562